London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a Non-Executive Director of the Group.
Mr. Soland was previously Senior Vice President and Chief Operating Officer of ViroPharma from 2008 until its acquisition by Shire in 2014. Prior to this he served as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his time at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States.
Prior to this, Mr. Soland was President at Chiron Vaccines from 2005 to 2006. During this time he oversaw the growth of the vaccine business to more than $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals.
Mr. Soland began his career at GlaxoSmithKline in 1993, occupying a number of roles including Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of Tarsa Therapeutics, DBV Technologies SA., and ACADIA Pharmaceuticals.
John Dawson, CEO of Oxford BioMedica, commented: “Daniel is a highly experienced biopharmaceutical executive with an outstanding track-record of leadership and innovation. As we continue to focus on driving our business forward, his knowledge of the US environment and extensive experience of clinical development and launching of new drugs will prove invaluable. In addition, his experience in leading manufacturing and quality organisations is highly relevant as we look to continue expansion of our already successful OXB Solutions business. He is an excellent fit for Oxford BioMedica and we look forward to him joining our Board.”
Mr Soland’s appointment will commence with immediate effect.
- Ends -
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sarah MacLeod, Head of Communications
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700